CHA2DS2VA-pisteytys ja HAS-BLED-indeksi

Kirjallisuutta

1. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010 Feb;137(2):263-72. «PMID: 19762550»PubMed
2. Pisters R, Lane DA, Nieuwlaat R ym. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010;138(5):1093-100. «PMID: 20299623»PubMed
3. Lip GY, Frison L, Halperin JL ym. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol 2011;57(2):173-80. «PMID: 21111555»PubMed
4. Lip GY. Implications of the CHA(2)DS(2)-VASc and HAS-BLED Scores for thromboprophylaxis in atrial fibrillation. Am J Med 2011;124(2):111-4. «PMID: 20887966»PubMed
5. Van Staa TP, Setakis E, Di Tanna GL ym. A comparison of risk stratification schemes for stroke in 79,884 atrial fibrillation patients in general practice. J Thromb Haemost 2011;9:39-48 «PMID: 21029359»PubMed
6. Kirchhof P, Benussi S, Kotecha D et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016 Oct 7;37(38):2893-2962. «PMID: 27567408»PubMed
7. Penttilä T, Lehto M, Niiranen J, ym. Differences in the risk of stroke, bleeding events, and mortality between female and male patients with atrial fibrillation during warfarin therapy. Eur Heart J Cardiovasc Pharmacother 2019;5(1):29-36 «PMID: 30052822»PubMed